TIPE2 and neoplasm: Although the TCGA tumor data shows positive relationship between TIPE2 and CD8, our preclinical data indicate that TIPE2 loss in MDSCs dictates the response to the combination therapy of the ferroptosis activator and immune therapy (Figure 5).